Group 1 - A class action has been filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025 [1] - The allegations state that Rocket Pharmaceuticals misled investors regarding the viability and efficacy of its RP-A501 drug, particularly concerning the Phase 2 pivotal trial for Danon disease [2] - Following the announcement of a Serious Adverse Event (SAE) related to the trial, Rocket's stock price dropped significantly from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025 [3] Group 2 - The complaint highlights that the company created a false impression of having reliable information about the trial's timeline and safety, which was contradicted by the reality of the situation [2] - The FDA placed the trial on hold due to the introduction of a novel immunomodulatory agent, which was part of an amended protocol that led to a patient's death [2] - Shareholders interested in participating in the class action can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025, due to allegations of misleading information regarding the company's clinical trial for RP-A501 [1][2]. Group 1: Allegations and Company Actions - The lawsuit claims that Rocket Pharmaceuticals misrepresented the viability and efficacy of RP-A501, particularly regarding the timeline and safety of its Phase 2 pivotal trial for Danon disease [2]. - It is alleged that the company provided an overly optimistic outlook on the trial's progress, which was contradicted by the reality of a Serious Adverse Event (SAE) that resulted in a patient's death after protocol amendments were made [2]. - Following the announcement of the SAE on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action can contact Robbins LLP to serve as lead plaintiff, representing other class members in the litigation [4]. - Shareholders are not required to take action to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the viability and efficacy of its gene therapy product RP-A501, particularly in relation to its Phase 2 clinical trial for Danon disease [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Rocket Pharmaceuticals misrepresented the reliability of information regarding the projected timeline and safety of the RP-A501 trial, leading to a false sense of security among investors [2]. - Following the announcement of a Serious Adverse Event (SAE) involving a patient in the trial, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, reflecting a significant loss in market value [3]. Group 2: Company Background - Rocket Pharmaceuticals is described as a fully integrated, late-stage biotechnology company focused on developing gene therapies for rare and severe diseases, emphasizing its commitment to clear clinical endpoints and direct on-target mechanisms of action [1]. Group 3: Legal Proceedings - Shareholders interested in participating in the class action can contact Robbins LLP, which is leading the litigation on a contingency fee basis, meaning no fees or expenses are required from shareholders [4][5].

Mustang Bio, Inc. As filed with the Securities and Exchange Commission on December 11, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 47-3828760 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 377 Planta ...